brolucizumab

FDA Drug Profile — BEOVU

Drug Details

Generic Name
brolucizumab
Brand Names
BEOVU
Application Number
BLA761125
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAVITREAL
Active Ingredients
BROLUCIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)